745 related articles for article (PubMed ID: 25936389)
1. Blood-brain barrier endogenous transporters as therapeutic targets: a new model for small molecule CNS drug discovery.
Pardridge WM
Expert Opin Ther Targets; 2015; 19(8):1059-72. PubMed ID: 25936389
[TBL] [Abstract][Full Text] [Related]
2. Blood-brain barrier genomics and the use of endogenous transporters to cause drug penetration into the brain.
Pardridge WM
Curr Opin Drug Discov Devel; 2003 Sep; 6(5):683-91. PubMed ID: 14579518
[TBL] [Abstract][Full Text] [Related]
3. Blood-brain barrier delivery.
Pardridge WM
Drug Discov Today; 2007 Jan; 12(1-2):54-61. PubMed ID: 17198973
[TBL] [Abstract][Full Text] [Related]
4. Blood-brain barrier models: in vitro to in vivo translation in preclinical development of CNS-targeting biotherapeutics.
Stanimirovic DB; Bani-Yaghoub M; Perkins M; Haqqani AS
Expert Opin Drug Discov; 2015 Feb; 10(2):141-55. PubMed ID: 25388782
[TBL] [Abstract][Full Text] [Related]
5. Mfsd2a-based pharmacological strategies for drug delivery across the blood-brain barrier.
Wang JZ; Xiao N; Zhang YZ; Zhao CX; Guo XH; Lu LM
Pharmacol Res; 2016 Feb; 104():124-31. PubMed ID: 26747400
[TBL] [Abstract][Full Text] [Related]
6. Drug transport across the blood-brain barrier.
Pardridge WM
J Cereb Blood Flow Metab; 2012 Nov; 32(11):1959-72. PubMed ID: 22929442
[TBL] [Abstract][Full Text] [Related]
7. Blood-brain barrier transporters: a translational consideration for CNS delivery of neurotherapeutics.
Ronaldson PT; Davis TP
Expert Opin Drug Deliv; 2024; 21(1):71-89. PubMed ID: 38217410
[TBL] [Abstract][Full Text] [Related]
8. Niosomes decorated with dual ligands targeting brain endothelial transporters increase cargo penetration across the blood-brain barrier.
Mészáros M; Porkoláb G; Kiss L; Pilbat AM; Kóta Z; Kupihár Z; Kéri A; Galbács G; Siklós L; Tóth A; Fülöp L; Csete M; Sipos Á; Hülper P; Sipos P; Páli T; Rákhely G; Szabó-Révész P; Deli MA; Veszelka S
Eur J Pharm Sci; 2018 Oct; 123():228-240. PubMed ID: 30031862
[TBL] [Abstract][Full Text] [Related]
9. Transporters at CNS barrier sites: obstacles or opportunities for drug delivery?
Sanchez-Covarrubias L; Slosky LM; Thompson BJ; Davis TP; Ronaldson PT
Curr Pharm Des; 2014; 20(10):1422-49. PubMed ID: 23789948
[TBL] [Abstract][Full Text] [Related]
10. Drug Delivery Strategies to Overcome the Blood-Brain Barrier (BBB).
Helms HCC; Kristensen M; Saaby L; Fricker G; Brodin B
Handb Exp Pharmacol; 2022; 273():151-183. PubMed ID: 33367937
[TBL] [Abstract][Full Text] [Related]
11. Strategies to improve drug delivery across the blood-brain barrier.
de Boer AG; Gaillard PJ
Clin Pharmacokinet; 2007; 46(7):553-76. PubMed ID: 17596102
[TBL] [Abstract][Full Text] [Related]
12. Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development.
Ohtsuki S; Terasaki T
Pharm Res; 2007 Sep; 24(9):1745-58. PubMed ID: 17619998
[TBL] [Abstract][Full Text] [Related]
13. Learning from our failures in blood-brain permeability: what can be done for new drug discovery?
Martel S
Expert Opin Drug Discov; 2015 Mar; 10(3):207-11. PubMed ID: 25658294
[TBL] [Abstract][Full Text] [Related]
14. [Multi-disciplinary research approaches on the brain barrier transport system, a dynamic interface].
Tachikawa M; Uchida Y; Terasaki T
Brain Nerve; 2013 Feb; 65(2):121-36. PubMed ID: 23399670
[TBL] [Abstract][Full Text] [Related]
15. Glucose promoiety enables glucose transporter mediated brain uptake of ketoprofen and indomethacin prodrugs in rats.
Gynther M; Ropponen J; Laine K; Leppänen J; Haapakoski P; Peura L; Järvinen T; Rautio J
J Med Chem; 2009 May; 52(10):3348-53. PubMed ID: 19402664
[TBL] [Abstract][Full Text] [Related]
16. Blood-brain barrier receptors and transporters: an insight on their function and how to exploit them through nanotechnology.
Moura RP; Martins C; Pinto S; Sousa F; Sarmento B
Expert Opin Drug Deliv; 2019 Mar; 16(3):271-285. PubMed ID: 30767695
[TBL] [Abstract][Full Text] [Related]
17. Drug targeting to brain: a systematic approach to study the factors, parameters and approaches for prediction of permeability of drugs across BBB.
Nagpal K; Singh SK; Mishra DN
Expert Opin Drug Deliv; 2013 Jul; 10(7):927-55. PubMed ID: 23330786
[TBL] [Abstract][Full Text] [Related]
18. In-vitro blood-brain barrier models for drug screening and permeation studies: an overview.
Bagchi S; Chhibber T; Lahooti B; Verma A; Borse V; Jayant RD
Drug Des Devel Ther; 2019; 13():3591-3605. PubMed ID: 31695329
[TBL] [Abstract][Full Text] [Related]
19. Mimicking brain tissue binding in an in vitro model of the blood-brain barrier illustrates differences between in vitro and in vivo methods for assessing the rate of brain penetration.
Heymans M; Sevin E; Gosselet F; Lundquist S; Culot M
Eur J Pharm Biopharm; 2018 Jun; 127():453-461. PubMed ID: 29602020
[TBL] [Abstract][Full Text] [Related]
20. Intriguing possibilities and beneficial aspects of transporter-conscious drug design.
Tashima T
Bioorg Med Chem; 2015 Aug; 23(15):4119-4131. PubMed ID: 26138194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
